<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00127582</url>
  </required_header>
  <id_info>
    <org_study_id>GUP02067</org_study_id>
    <nct_id>NCT00127582</nct_id>
  </id_info>
  <brief_title>RAMYD Study - Evaluation of Arrhythmic Risk in Myotonic Dystrophy</brief_title>
  <official_title>Evaluation of Arrhythmic Risk in Myotonic Dystrophy Type I (DM 1)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Catholic University of the Sacred Heart</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fondazione Telethon</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Catholic University of the Sacred Heart</source>
  <brief_summary>
    <textblock>
      This is a prospective multicentric Italian study to evaluate the arrhythmic risk in myotonic&#xD;
      dystrophy type 1.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Myotonic dystrophy type 1 (DM1, Steinert disease) is a multisystem disorder that affects,&#xD;
      beside muscle, several other organs, including the heart.&#xD;
&#xD;
      Cardiac involvement represents a major problem in the clinical management of patients, so&#xD;
      that cardiac complications represent one of the primary causes of premature death in DM1. In&#xD;
      particular there is a high incidence of sudden death, ranging from 2 to 30% of cases, so far&#xD;
      principally related to the development of conduction blocks. However, literature reports of&#xD;
      sudden death in patients implanted with pacemakers, as well as of spontaneous ventricular&#xD;
      tachycardia would suggest a potential etiologic role also for ventricular arrhythmias. The&#xD;
      lack of clinical research studies conducted on a large number of patients does not make&#xD;
      available definite data regarding the etiology and the epidemiology of arrhythmic events in&#xD;
      DM1. For the same reasons, other considerable topics, such as prognostic stratification of&#xD;
      the arrhythmic risk and clinical management of life-threatening arrhythmias in DM1 patients,&#xD;
      are still undefined.&#xD;
&#xD;
      To clarify these issues, the investigators propose a clinical research study performed on a&#xD;
      large cohort of DM1 patients enrolled through a multicenter collaboration that also involves&#xD;
      5 cardiological-neurological Italian centres.&#xD;
&#xD;
      Aims of this study are:&#xD;
&#xD;
        -  To estimate the incidence of arrhythmias and to characterize the brady-tachyarrhythmic&#xD;
           mechanisms underlying the occurrence of cardiac sudden death in DM1;&#xD;
&#xD;
        -  To verify by statistical analysis the reliability of data obtained from both non&#xD;
           invasive and invasive diagnostic procedures as indexes useful for estimating the&#xD;
           arrhythmic risk in DM1;&#xD;
&#xD;
        -  To identify more adequate therapeutic guidelines in order to prevent the occurrence of&#xD;
           life-threatening arrhythmias.&#xD;
&#xD;
      The protocol of study includes:&#xD;
&#xD;
        1. Clinical-genetic evaluation;&#xD;
&#xD;
        2. Non invasive and invasive diagnostic cardiac procedures;&#xD;
&#xD;
        3. The use of devices for diagnostic and therapeutic follow-up.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2003</start_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate incidence of: major cardiac events (sudden death</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>resuscitated cardiac arrest</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>ventricular fibrillation</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>sustained ventricular tachycardia</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>sinoatrial and atrioventricular [AV] blocks)</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate with diagnostic non-invasive (standard electrocardiogram [ECG]</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>24-hour monitoring ECG</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>signal-averaged ECG</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>echocardiography) and invasive procedures (electrophysiology study [EPS] and implantable loop recorders) the risk to develop cardiac arrhythmias in DM patients</measure>
  </secondary_outcome>
  <enrollment>537</enrollment>
  <condition>Myotonic Dystrophy</condition>
  <condition>Sudden Cardiac Death</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Electrophysiological study</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>pacemaker (PM) implant, internal cardiac defibrillator (ICD) implant, loop-recorder implant</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient affected by myotonic dystrophy type I (MD1).&#xD;
&#xD;
          -  Patient willing to provide a signed informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age &lt; 18 years old or &gt;70 years old.&#xD;
&#xD;
          -  Ischemic cardiomyopathy&#xD;
&#xD;
          -  Cardiomyopathy due to chronic excess of alcohol consumption (&gt;100 g\day)&#xD;
&#xD;
          -  Congenital heart disease&#xD;
&#xD;
          -  Acquired valvular heart disease&#xD;
&#xD;
          -  Metabolic cardiomyopathy: thyrotoxicosis, hypothyroidism, adrenal cortical&#xD;
             insufficiency, pheochromocytoma, acromegaly&#xD;
&#xD;
          -  Familiar storage and infiltrative diseases (hemochromatosis, glycogen storage,&#xD;
             Hurler's syndrome, Niemann-Pick disease; primary, secondary, familial and hereditary&#xD;
             cardiac amyloidoses)&#xD;
&#xD;
          -  Systemic diseases (connective tissue disorder; sarcoidosis)&#xD;
&#xD;
          -  Peripartum cardiomyopathy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fulvio Bellocci, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Catholic University of Sacred Heart</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Fulvio Bellocci, MD</last_name>
    <phone>+390630154187</phone>
    <email>adellorusso@tin.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Antonio Dello Russo, MD</last_name>
    <phone>+393393971873</phone>
    <email>adellorusso@tin.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Catholic University of Sacred Heart</name>
      <address>
        <city>Rome</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fulvio Bellocci, MD</last_name>
      <phone>+390630154187</phone>
      <email>adellorusso@tin.it</email>
    </contact>
    <investigator>
      <last_name>Fulvio Bellocci, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Pelargonio G, Dello Russo A, Sanna T, De Martino G, Bellocci F. Myotonic dystrophy and the heart. Heart. 2002 Dec;88(6):665-70. Review.</citation>
    <PMID>12433913</PMID>
  </reference>
  <verification_date>May 2005</verification_date>
  <study_first_submitted>August 4, 2005</study_first_submitted>
  <study_first_submitted_qc>August 4, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 8, 2005</study_first_posted>
  <last_update_submitted>August 24, 2005</last_update_submitted>
  <last_update_submitted_qc>August 24, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 25, 2005</last_update_posted>
  <keyword>Myotonic dystrophy type 1</keyword>
  <keyword>Sudden cardiac death</keyword>
  <keyword>Ventricular tachyarrhythmias</keyword>
  <keyword>Bradyarrhythmias</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myotonic Dystrophy</mesh_term>
    <mesh_term>Death, Sudden, Cardiac</mesh_term>
    <mesh_term>Death</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

